Avra Medical Robotics, Logo

Precision Guided Surgical Robotics.

Toll Free +1 (866) 205-4430

Translate this page:

Follow Us On
Facebook IconLinkedIn Icon

AVRA Medical Robotics, Inc. Updates Shareholders and the Investment Community With Respect to Recent Events Raising AVRA’s Visibility in the Medical Robotics Field

ORLANDO, Fla., Sept. 21, 2017 (GLOBE NEWSWIRE) -- AVRA Medical Robotics, Inc. (“AVRA”), which is planning to enter the field of medical robotics through the development of an intelligent medical robotic system for skin resurfacing procedures in partnership with the University of Central Florida, today updated its shareholders and the investment community with respect to a number of recent events which have raised AVRA’s visibility in the medical robotics field.

In August 2017, at the request of IBM, AVRA provided them with their medical robotic prototype to appear in one of their IBM Watson commercials. The commercial, which has been filmed and which, in versions supplied to the Company, has the prototype and the AVRA logo visible, is scheduled to air over the next 12 months as part of IBM’s Watson series of commercials.

Secondly, AVRA was invited to present at the Swedish American Life Science Summit (SALSS) held August 23-25, 2017 in Stockholm, Sweden. At SALSS, AVRA placed second as a Rising Star among many other impressive technology companies. AVRA was represented at SALSS by Dr. Nikhil Shah, a member of the Company’s board of directors, Dr. Farhan Taghizadeh, AVRA Chief Medical Officer, and Alen York, a senior advisor to AVRA management.

Finally, AVRA was invited by Admiral Michael Cowan, Director of AMSUS, the Society of Federal Health Professionals, to join key medical and governmental organizations, including Intuitive Surgical, and attend a roundtable discussing ways to reduce the number of preventable deaths due to surgical trauma. AVRA was represented at this event, which was held at the Army Navy Club on August 21, 2017 in Washington, DC by Barry F. Cohen, AVRA Chief Executive Officer and Alexandre Clug, AVRA Vice President of Global Business Development.

For further information contact:

Barry F. Cohen
About AVRA Medical Robotics, Inc.

AVRA Medical Robotics, Inc., (“AVRA”) is planning to enter the medical robotics field through the development of an intelligent medical robotic system for skin resurfacing procedures, in partnership with the University of Central Florida (“UCF”). AVRA was organized by a senior leadership team with broad and deep experience in medical research, innovation and development in the medical robotics field. AVRA is concentrating on the growing demand for practical medical robotic devices by developing a platform-independent precision guidance system, applicable to a variety of minimally invasive and non-invasive procedures, with an initial focus on skin resurfacing. The skill and experience of its leadership team is enhanced by the active participation in development of UCF, which is recognized particularly for its work in the area of medical robotics research and design. Moreover, AVRA’s leadership team is also experienced in marketing, chain management, and the implementation of all other aspects of business operations.

Forward-Looking Statements

This press release may contain statements that are not historical facts and are considered forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. We use the words “anticipate,” “assume,” “believe,” “estimate,” “expect,” “will,” “intend,” “may,” “plan,” “project,” “should,” “could,” “seek,” “designed,” “potential,” “forecast,” “target,” “objective,” “goal,” or the negatives of such terms or other similar expressions to identify such forward-looking statements. These statements relate to future events or AVRA’s future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements.
Source: AVRA Medical Robotics, Inc 

Swedish American Group Focuses On Cancer, Autoimmune Diseases At Life Science Summit

Gene Marcial , Contributor
September 09 2017

Respected and acclaimed as rock stars in the arcane universe of life sciences, global scientists converged in Stockholm in late August this year for the annual Swedish American Life Science Summit (SALSS) meeting, where they unveiled and dissected revolutionary health care platforms. Among them are the use of robotics in surgery, how nanotechnology may make us "forever young,” applications of space technology in life sciences, and the “Moonshot” cancer program initiated by former Vice President Joseph Biden..........


“Part of this year’s conference focus was the current transformation of the HealthTech industry, driven by the ICT and tech players rather than by the traditional medtech companies,” said Barbro C. Ehnbom, chairman and founder of SALSS. Also significant, she added, was the participation of numerous women at this year’s summit, led by the keynote speaker Dr. Bahija Jallal, executive vice president at AsraZeneca and head of Medimmune. “ We are proud and glad that so many prominent women are actually SALSS women, including Dr. Jallal, which made this 2017 summit more exceptional,” said Ms. Ehnbom.

One of the little known companies that attracted a lot of attention at the conference was AVRA Medical Robotics, a development-stage company based in Orlando, Florida, that has a new generation of “semi-autonomous medical robots for image-capture, navigation, and tissue targeting.”

Specifically, these “medical robots” perform computer-assisted surgery, with human medical surgeons operating a remote surgical device via a console. In fact, they are not really robots as we know them: AVRA has developed a "novel and truly robotic single-arms platform for the field of aesthetics, skin and wound care as well as dermato-plastic surgery,” said Barry F. Cohen, AVRA’s CEO and founder. The company’s first design integrates software, image guidance, navigation and targeting systems, to allow autonomous needling of skin, he explained.

“The future of surgery will be determined by success in gaining precision access to anny area of the human body with the smallest incisions and deploying therapies to specific tissues, glands and organs,” asserted Alen York, an AVRA senior executive. Limitations in conventional surgeries, he said, are "demanding more autonomous, intelligent robot systems that go beyond the capability of a human being.”

AVRA’S platform focused on needling technology "represents a key breakthrough in aesthetics, wound care, and autonomous drug delivery platforms, integration of artificial intelligence and augmented reality that will allow,” says York, for a new paradigm in surgical training, planning and treatment.

For complete article please visit forbes.com

Young Woman on a Computer with an Older Man

Medical Robotics Company Harnesses UCF Research for Computer-Aided Surgery

A medical robotics company has licensed University of Central Florida expertise to develop software for a new surgical-robotic platform.
AVRA Medical Robotics Inc., which has an office in the UCF Business Incubator, has partnered with Professor Zhihua Qu and Research Professor Eytan Pollak of the College of Engineering & Computer Science to develop algorithms and sensors to navigate and control a robot capable of assisting physicians with performing minimally invasive surgical procedures in an ambulatory setting or operating room.

Barry F. Cohen, AVRA founder and chairman, said he was drawn to UCF because of its engineering strength for the development of a modular, robotic-assistive system that will be portable, precise and affordable.

"UCF research is providing the precision and guidance necessary for a computer-driven robotic system that will facilitate superior outcomes," Cohen said.

AVRA partnered with a new industry-sponsored innovation program at UCF by providing $200,000 initially with planned follow-up funding for the research and the rights to any intellectual property developed during the project. In addition, AVRA will pay UCF 1 percent in royalty fees for annual sales exceeding $20 million resulting from the intellectual property.

"At UCF we encourage the collaboration between our research and industry. Initiatives such as this innovation program help streamline the process and move pioneering research into the market," said Elizabeth Klonoff, vice president for research and dean of the College of Graduate Studies.

Qu and Pollak have extensive backgrounds in the development of computer-operated systems that encompass the integration of tools and sensors, real-time image/data processing, navigation, control and human-machine interface. Qu's research has included robotic platforms and autonomous vehicles for the Department of Defense, applications and intelligent robotic systems for life support on Mars among others, autonomous coordination of robotic devices, and human-robot teaming.

Deepalakshmi Babu Venkateswaran

Pollak has 30 years' experience in managing complex research and development programs, holds several patents and has published papers in control systems and robotics. He is also the director of strategic technologies at L-3 Communications Link Simulation & Training.

Based on an original concept proposed by Qu, his graduate students, Niladri Basu Bal and Deepalakshmi Babu Venkateswaran, have implemented navigation/control algorithms and completed a 3-D computer visualization of how such a robotic device would work. Computer-aided design and development of a graphic user interface for surgeons are now under way.

AVRA has recently added some industry partners to its team. Anthony Nicholson, a longtime benefactor of UCF, serves as a senior advisor of the company, and Peter Carnegie, CEO of Minimally Invasive Solutions in Ocoee, and Dr. Nikhil Shah of Atlanta, are new directors.


UCF Grad Students Developing Robot to Help With Precise Surgical Procedures

A group of college students is working to develop a robot that could revolutionize the medical industry.